

I. AMENDMENTS

Please enter the amendments to the claims filed in response to the Final Office Action, issued June 26, 2002 and enter the following new amendments to the claims.

Amend claims 1 and 49 and cancel claims 42 and 43, without prejudice or disclaimer.

D 1
1. (Twice Amended) An isolated nucleic acid molecule comprising a sequence that has at least about 85% 90% sequence identity to SEQ ID NO:1 or a complementary sequence thereof, wherein the nucleic acid encodes a polypeptide that binds a C terminus of GRIP1.

2. (Reiterated) A recombinant vector comprising the nucleic acid molecule of Claim 1.

3. (Reiterated) A genetically engineered cell comprising the recombinant vector of Claim 2.

39. (Reiterated) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising SEQ ID NO:2.

40. (Reiterated) A recombinant vector comprising the nucleic acid molecule of claim 39.

41. (Reiterated) A genetically engineered cell comprising the recombinant vector of claim 40.

42. (Cancel) ~~The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a sequence that has at least about 90% sequence identity to SEQ ID NO:1.~~

43. (Cancel) ~~A recombinant vector comprising the nucleic acid molecule of claim 42.~~

44. (Reiterated) A genetically engineered cell comprising the recombinant vector of claim 43.

U.S.S.N: 09/464,377
Attorney Docket No: 13761-0726-US1
Client Docket No: 2804

45. (Reiterated) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a sequence that has at least about 95% sequence identity to SEQ ID NO:1.

46. (Reiterated) A recombinant vector comprising the nucleic acid molecule of claim 45.

47. (Reiterated) A genetically engineered cell comprising the recombinant vector of claim 46.

48. (Reiterated) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises SEQ ID NO:1.

D 2
49. (Amended) A recombinant vector comprising the nucleic acid molecule of claim 45
48.

50. (Reiterated) A genetically engineered cell comprising the recombinant vector of claim 46.

51. (Reiterated) The isolated nucleic acid molecule of claim 1, wherein the polypeptide comprises methyltransferase activity.

52. (Reiterated) The isolated nucleic acid molecule of claim 1, wherein the polypeptide comprises coactivator activity.

II. REMARKS

STATUS OF THE CLAIMS

Claims 1-47 were pending in this application. Claims 4-38 have been cancelled without prejudice, having been withdrawn from consideration due to election after a restriction requirement. Claims 1 and 49 have been amended herein and claims 42 and 43 have been canceled without prejudice or disclaimer. Support for the amendment to claim 1 is found on page 15, line 9 of the specification as originally filed. Claim 49 has been amended to correct a typographical error and support for the amendment to claim 49 is found in the specification on

U.S.S.N: 09/464,377
Attorney Docket No: 13761-0726-US1
Client Docket No: 2804